
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
Are you ready for a career coach and change in pharmacy?
Are you ready for a career coach and change in pharmacy?






